Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116256 | 0.98 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL1101908 | 0.80 | KDM4E (0.94) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL14955079 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL7913275 | 0.79 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL1102006 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL7903020 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL8388801 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL1101919 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL23782803 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A | |
| SCHEMBL4107462 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EALDH1A1HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | SMN1; SMN2 524/4885KDM4E 2385/4885ALDH1A1 2811/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | SMN1; SMN2 524/4885KDM4E 2385/4885ALDH1A1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.